What type of cancer is Daurismo (glasdegib) used to treat?

Daurismo (glasdegib) is an oral hedgehog pathway inhibitor used with low-dose cytarabine (LDAC) chemotherapy for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older or for patients unable to use intensive chemotherapy.

• AML is a blood and bone marrow cancer that leads to abnormal white blood cells, bruising, fatigue, and infections.
• Many adults with AML are unable to have intensive chemotherapy due to toxicity.
• Daurismo may be a more tolerable option for some AML patients.

The hedgehog pathway is a novel therapeutic cancer target. The hedgehog signaling pathway is involved in the normal, early stages of cell growth of a fetus. However, mutation of this pathway in adults can lead to the development of certain cancers, such as skin, brain, pancreatic, prostate, and lung cancers and hematological malignancies like AML.